Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Alveolar Proteinosis Clear all
Terminated Phase 2 Interventional

GM-CSF in Patients With Pulmonary Alveolar Proteinosis

NCT00030056
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis
Interventions
GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jun 9, 2026, 11:38 PM EDT
Completed No phase listed Observational

The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis

NCT03531996
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jun 9, 2026, 11:38 PM EDT
Not listed Early Phase 1 Interventional

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

NCT04326036
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia, Coronavirus Infection, Interstitial Lung Disease
Interventions
Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution, Liberase Enzyme (Roche), Sterile Normal Saline for Intravenous Use
Procedure · Device · Drug
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Jun 9, 2026, 11:38 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

NCT04544293
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim, Placebo, Molgramostim Open-label
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis

NCT03006146
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Sargramostim
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Los Altos, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Jun 9, 2026, 11:38 PM EDT
Available No phase listed Expanded access

Molgramostim Nebulizer Solution Expanded Access Program Protocol

NCT06546098
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim nebulizer solution
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
U.S. locations
6
States / cities
Los Angeles, California • Gainesville, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 9, 2026, 11:38 PM EDT
Completed No phase listed Observational

Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT

NCT02081092
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Jun 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

NCT03231033
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Pioglitazone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jun 9, 2026, 11:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of PMT Therapy of hPAP

NCT05761899
View directory record Official record
Conditions
Hereditary Pulmonary Alveolar Proteinosis
Interventions
Gene-Corrected Macrophages administered by bronchoscopic instillation
Combination Product
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

NCT02702180
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim, Placebo, PARI eFlow nebulizer system
Drug · Device
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Gainesville, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Jun 9, 2026, 11:38 PM EDT
Completed No phase listed Observational

Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial

NCT03007134
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis
Interventions
Retrospective Chart Review
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Greenville, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Jun 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional

Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

NCT00552461
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis, Primary Disease
Interventions
rituximab
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jun 9, 2026, 11:38 PM EDT
Recruiting No phase listed Observational

A National Registry For Pulmonary Alveolar Proteinosis

NCT02461615
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)

NCT01511068
View directory record Official record
Conditions
Hereditary Pulmonary Alveolar Proteinosis
Interventions
Leukine
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Jun 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

NCT01842386
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 9, 2026, 11:38 PM EDT